Bioteque (4107) Q4 2025 earnings summary

Executive summary

• Consolidated financial statements for the years ended December 31, 2025 and 2024 were audited and present fairly in all material respects in accordance with IFRS as endorsed by the FSC of Taiwan.

• The business focuses on manufacturing, trading, and selling medical consumables, with operations in Taiwan and subsidiaries in the Philippines.

Financial highlights

• Operating revenue for 2025 was NT$2,135,451 thousand, up 3% year-over-year from NT$2,072,575 thousand in 2024.

• Net profit for 2025 was NT$539,185 thousand, a 2% increase from NT$528,260 thousand in 2024.

• Gross margin remained stable at 44% for both years.

• Basic EPS for 2025 was NT$7.78, up from NT$7.62 in 2024.

• Cash dividends per share increased to NT$5.50 for 2025, compared to NT$5.00 for 2024.

Outlook and guidance

• Adoption of new IFRS standards is not expected to have a significant impact; IFRS 18 will be adopted in 2028.

• The Group is evaluating the impact of future standards and will disclose results upon completion.